← Back to Clinical Trials
Recruiting NCT07436754

NCT07436754 Clinical Trial Comparing the Efficacy of Two Teletherapy Programs at Improving Psychological Health in People With Brain Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07436754
Status Recruiting
Phase
Sponsor Hackensack Meridian Health
Condition Mild Traumatic Brain Injury
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2026-05-20
Primary Completion 2031-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Program 1Program 2

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2026-05-20 with a primary completion date of 2031-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of the study is to test two different training programs to find out which is better at helping people with a concussion or mild TBI (mTBI) improve their emotional health and well-being. Study participation is completely remote and will last approximately 8 months total, involving 4 assessment visits and 8 sessions of brain training via a secure video-conferencing platform. The 4 assessment visits (about 30-90 minutes each) include surveys and questionnaires about participant's emotional health. These assessment visits will take place before the training, immediately after the training, 3 months after training and 6 months after training. The 8 sessions of 1-on-1 training (about 60-90 minutes each) will be completed over the course of approximately 1 month.

Eligibility Criteria

Inclusion Criteria: * Mild TBI * ≥18 years old * ≥6 months post-TBI * Elevated alexithymia and emotion dysregulation * Capacity to consent * Speaks and understands English * Personal device capable of video conferencing and internet Exclusion Criteria: * Premorbid neurological disorder other than TBI * Degenerative neurologic condition * Active or uncontrolled major psychiatric disorder * Conditions that pose safety concern to self or others, such as suicide risk * Previous psychiatric hospitalization * Visual, hearing, communication, or cognitive impairments that would impede participation * Unstable medications (e.g., started \< 6 weeks prior to enrollment) or anticipated medication changes that will influence mood/ affect during study participation * Active involvement in an intensive rehabilitation program * Individuals who recently started psychotherapy and/or mental health counseling (e.g., \<3 months prior)

Contact & Investigator

Central Contact

Grace Wells

✉ grace.wells1@hmhn.org

📞 732-321-7000

Principal Investigator

Dawn Neumann, PhD, FACRM

PRINCIPAL INVESTIGATOR

Hackensack Meridian Health

Frequently Asked Questions

Who can join the NCT07436754 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mild Traumatic Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07436754 currently recruiting?

Yes, NCT07436754 is actively recruiting participants. Contact the research team at grace.wells1@hmhn.org for enrollment information.

Where is the NCT07436754 trial being conducted?

This trial is being conducted at Indianapolis, United States, Bethesda, United States, Edison, United States.

Who is sponsoring the NCT07436754 clinical trial?

NCT07436754 is sponsored by Hackensack Meridian Health. The principal investigator is Dawn Neumann, PhD, FACRM at Hackensack Meridian Health. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology